Nasal drug delivery market seen reaching $129.23 billion by 2030

The nasal drug delivery technology market is projected to grow from $92.28 billion in 2026 to $129.23 billion by 2030, driven by demand for faster, non-invasive therapies and more work in CNS drugs and vaccines. North America held the largest share in 2025, according to The Business Research Company.

Why it matters: - Nasal drug delivery is gaining traction as a faster, non-invasive way to deliver medicines, including therapies that may reach the brain more directly. - The market’s projected rise signals growing demand for patient-friendly drug delivery systems in chronic disease care, CNS treatment and vaccine development.

What happened: - The Business Research Company released a 2026 market report on the nasal drug delivery technology market. - The market is projected to grow from $85.23 billion in 2025 to $92.28 billion in 2026. - The market is expected to reach $129.23 billion by 2030. - The forecast implies an 8.8% CAGR from 2026 to 2030. - North America held the largest market share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available. - The full market report is also available.

The details: - Nasal drug delivery technology administers drugs through the nasal cavity to reach therapeutic levels in the bloodstream quickly. - The approach can also enable direct delivery to the brain through olfactory neurons. - The method bypasses the blood-brain barrier and avoids extensive processing by the liver and intestines. - Historical growth was driven by rising respiratory and neurological disorders, higher demand for non-invasive delivery, more nasal allergy treatments, and wider adoption of self-administration devices. - Future growth is expected to come from more investment in CNS drug development, demand for fast-acting therapies, nasal vaccine research, patient-friendly delivery systems and new nasal formulations. - Emerging trends include wider use of nasal sprays, more brain-targeted delivery, new nasal devices, broader vaccine and emergency use, and greater focus on rapid absorption. - Chronic diseases are a major growth driver because they often require ongoing management and reduce quality of life. - Nasal drug delivery is especially useful for chronic rhinosinusitis and other persistent airway disorders. - In June 2024, the UK National Health Service reported that 3,615,330 registered patients were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023. - That figure was up 18% from 3,065,825 cases in 2022.

Between the lines: - The report points to a market shift from convenience alone toward therapies that can support faster onset and potentially better targeting. - The emphasis on CNS drugs and brain delivery suggests the field is moving beyond routine nasal treatments into higher-value pharmaceutical applications. - The chronic disease data helps explain why drug makers are focusing on delivery formats that can improve adherence and ease of use.

What's next: - Expect more investment in nasal formulations, device design and brain-targeted drug research. - The company’s broader 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards, hotspot graphics and updated tables.